Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status. See our latest analysis for Teva Pharmaceutical Industries. The ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum...

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High - Here

X Square Capital LLC bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 56,230 shares of the company

In August 2026, Teva Pharmaceuticals announced that the FDA accepted and granted Priority Review to its New Drug Application for ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette syndrome, supported by positive Phase 2b and Phase 3 data and backed by Orphan Drug designation. If approved, ecopipam could become the first new pediatric Tourette syndrome treatment in more than a decade and introduce a novel mechanism of action in this condition for the first time in over...

Aurinia Pharmaceuticals ha llegado a un acuerdo de patente con Teva Pharmaceutical Industries que impide a Teva lanzar una versión genérica de…